Key terms
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GILD news
Apr 30
6:55am ET
Gilead Sciences: Hold Rating Justified Amid Stable Outlook and Upcoming Oncology Catalysts
Apr 30
6:33am ET
Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)
Apr 30
3:00am ET
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and SAGE Therapeutics (SAGE)
Apr 30
2:51am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC), R1 RCM (RCM) and Gilead Sciences (GILD)
Apr 30
2:31am ET
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and Sanofi (OtherSNYNF)
Apr 29
5:48am ET
Gilead price target lowered to $76 from $80 at Barclays
Apr 27
12:20am ET
Analysts Are Neutral on These Healthcare Stocks: Edwards Lifesciences (EW), Gilead Sciences (GILD)
Apr 26
8:48am ET
Gilead price target lowered to $85 from $90 at TD Cowen
Apr 26
8:25am ET
Gilead announces FDA approval for updated Biktarvy label
Apr 26
8:21am ET
Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Gilead Sciences (GILD)
Apr 26
8:05am ET
Gilead price target lowered to $74 from $76 at RBC Capital
Apr 26
7:50am ET
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Teladoc (TDOC) and Gilead Sciences (GILD)
Apr 26
7:30am ET
Truist Financial Reaffirms Their Hold Rating on Gilead Sciences (GILD)
Apr 26
7:26am ET
Gilead Sciences: A Strong Buy on Robust Sales and Promising Future Catalysts
Apr 26
6:42am ET
Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Rhythm Pharmaceuticals (RYTM) and Dexcom (DXCM)
Apr 26
6:30am ET
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Globus Medical (GMED) and Merck & Company (MRK)
Apr 25
4:03pm ET
Gilead cuts FY24 adjusted EPS view to $3.45-$3.85 from $6.85-$7.25
Apr 25
4:02pm ET
Gilead reports Q1 adjusted EPS ($1.32), consensus ($1.39)
Apr 25
3:19pm ET
Gilead options imply 3.2% move in share price post-earnings
Apr 25
1:09pm ET
Notable companies reporting after market close
Apr 25
8:21am ET
Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Gilead Sciences (GILD)
Apr 25
7:05am ET
Options Volatility and Implied Earnings Moves Today, April 25, 2024
Apr 24
1:27pm ET
Gilead upgraded to Hold from Reduce at HSBC
Apr 22
7:19am ET
Gilead price target lowered to $75 from $78 at Cantor Fitzgerald
Apr 22
7:01am ET
Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
Apr 22
1:20am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Owens & Minor (OMI), Bruker (BRKR) and Gilead Sciences (GILD)
Apr 19
7:50am ET
Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB)
Apr 18
6:06am ET
Hold Rating on Gilead Sciences Amidst Q1 Revenue Shortfall and Acquisition Concerns
Apr 08
10:50pm ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Gilead Sciences (GILD) and Agios Pharma (AGIO)
Apr 08
3:18pm ET
Fly Insider: Xilio, Aerovate among weekâs notable insider trades
Apr 02
7:12am ET
Nurix Therapeutics announces extension of collaboration with Gilead
GILD Financials
Key terms
Ad Feedback
GILD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GILD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range